Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $192.5 million versus the consensus estimate of $199.47 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.